行情

CATB

CATB

Catabasis Pharms
NASDAQ

实时行情|Nasdaq Last Sale

5.53
-0.03
-0.54%
休市 16:00 12/13 EST
开盘
5.58
昨收
5.56
最高
5.74
最低
5.50
成交量
4.54万
成交额
--
52周最高
9.76
52周最低
3.600
市值
6,523.85万
市盈率(TTM)
-2.0848
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CATB 新闻

  • 约翰逊拒绝苏格兰“脱英” 脱欧后或大幅改组内阁
  • 中国新闻网.2小时前
  • 气候变化将对人类重要野生蔬菜构成灭绝威胁
  • 新浪财经综合.3小时前
  • 专家警告日本“绝种”风险!韩国问题更严重
  • 新浪财经综合.3小时前
  • 美政府调查第12起涉及特斯拉Autopilot交通事故
  • 新浪科技.3小时前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

CATB 简况

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
展开

Webull提供Catabasis Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。